California-based clinical stage biotech company Phanes Therapeutics, Inc. (Phanes) announced on Friday that it has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for its PT217, intended for the treatment of neuroendocrine carcinoma (NEC).
PT217, a first-in-class bispecific antibody, targeting delta-like ligand 3 (DLL3) and cluster of differentiation 47 (CD47) and is being developed for patients with NEC. It received ODD for the treatment of small cell lung cancer (SCLC) from the FDA in 2022, and was granted Fast Track designation by the agency in 2024 for the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression following platinum chemotherapy with or without a checkpoint inhibitor.
Earlier this year, Phanes signed a clinical supply agreement with Roche to study PT217 along with Roche's anti-PD-L1 therapy, atezolizumab.
Cumberland Pharmaceuticals partners Qureight for idiopathic pulmonary fibrosis treatment research
AstraZeneca and Daiichi Sankyo's Enhertu shows strong results in early-stage breast cancer trial
Phanes Therapeutics doses first patient in peluntamig-atezolizumab combination clinical study
Nutshell Therapeutics' NTS071 p53 allosteric reactivator cleared for US clinical trial
Innovent's limertinib receives Chinese regulatory approval for first-line treatment of lung cancer
bioMérieux launches PCR wastewater test to support early detection of infectious disease outbreaks
Clario partners with AWS on advancing clinical data analysis with generative AI
Zynext Ventures invests in Feldan Therapeutics
Sanofi advances respiratory pipeline with positive amlitelimab data and expanded clinical programmes
Sichuan Kelun-Biotech reveals sacituzumab tirumotecan (sac-TMT) clinical studies results
Amgen's IMDELLTRA shows superior overall survival in small cell lung cancer trial